Biodegradable Nanoparticles Improve Oral Bioavailability of Amphotericin B and Show Reduced Nephrotoxicity Compared to Intravenous Fungizone®

Italia, J.L.; Yahya, M. M.; Singh, Dinesh; Kumar, M. N. V. Ravi

doi:10.1007/s11095-009-9841-2

Cited by 127 publications

(74 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On addition of organic phase containing drug and polymer into aqueous phase, desolvation of polymer occured rapidly due to diffusion of solvent into aqueous phase. This resulted into precipitation of polymer along with drug entrapped into the polymer matrix, to give instantaneous formation of NP with drug distributed into the polymer matrix [8]. The nanoprecipitation technique was relatively straightforward and rapid, and offered reproducible particle size with a narrow distribution [9].…”

Section: Introductionmentioning

confidence: 99%

Critical Process Parameters Evaluation of Modified Nanoprecipitation Method on Lomustine Nanoparticles and Cytostatic Activity Study on L132 Human Cancer Cell Line

Mehrotra¹

2012

J Nanomedic Nanotechnol

View full text Add to dashboard Cite

This work was focused on identification and evaluation of process parameters of modified nanoprecipitation method, for fabrication of lomustine nanoparticles, with the aim of reducing cancer cell viability at low concentration of lomustine. The parameters controlling particle size, mostly in nanosize, were solvent/nonsolvent composition and emulsification speed of homogenizer along with aqueous phase volume. This controlled particle size is below 250 nm. The stabilizer concentration controlled particle size is within 68 nm ± 0.89 to 137 ± 0.94 nm with PDI 0.06 ± 0.008 to 0.25 ± 0.001. But, the stabilizer addition mode showed more uniform size distribution with PDI 0.085 ± 0.004. Entrapment efficiency was maintained well above 47 ± 0.23%. The drug release pattern was monophasic with controlled release over 24 hrs. In the method used, drug content was affected by ratio of polymer to drug to organic solvent, as well as homogenization speed and time. Percentage viable cells of L132 human lung cancer cell line remained, were only 5% at 100 µg/ml lomustine equivalent PLA nanoparticles. ethanol as a cosolvent, homogenization speed and time were evaluated affecting the particle size, encapsulation efficiency and in vitro drug release.

show abstract

Section: Introductionmentioning

confidence: 99%

Critical Process Parameters Evaluation of Modified Nanoprecipitation Method on Lomustine Nanoparticles and Cytostatic Activity Study on L132 Human Cancer Cell Line

Mehrotra¹

2012

J Nanomedic Nanotechnol

View full text Add to dashboard Cite

show abstract

“…Its employment is limited due to poor biodistribution, low solubility and high nephrotoxicity leading to kidney failure. In order to bypass these obstacles Italia et al entrapped amphotericin B into PLGA nanoparticles, which resulted in improvement or oral bioavailability and reduced nephrotoxicity [50]. Similar results from Tang et al [51] indicate increased fungicidal activity of amphotericin B after incorporation into polymeric nanoparticles.…”

Section: Recent Advances In Application Of Antibioticconjugated Nanopmentioning

confidence: 89%

Polymeric nanoparticles – a novel solution for delivery of antimicrobial agents

Michalak¹,

Głuszek²,

Piktel³

et al. 2016

View full text Add to dashboard Cite

The increased prevalence of antibiotic-resistant pathogens requires additional efforts to develop new antimicrobial agents and alternative methods to prevent and treat infections. In response to this challenge, a variety of nanotechnology-based tools are currently being designed and thoroughly investigated. To date, a considerable number of studies have reported increased activity of antibiotic-conjugated polymeric nanoparticles against bacteria and fungi associated with various infections, including those caused by drug-resistant pathogens. Importantly, high biocompatibility of these structures coupled with enhanced biological activity and improved pharmacokinetic properties supports the potential of these nanosystems as new tools to treat infections. In this review, we summarize the synthesis of polymer-based nanoparticles and describe their mechanism of action. We also highlight the recent advances in the application of antibiotic-conjugated polymeric nanoparticles as novel antimicrobial agents. StreszczenieStale narastająca lekooporność drobnoustrojów wymusza konieczność rozwoju alternatywnych metod profilaktyki i terapii zakażeń, a także uzasadnia prace nad nowymi lekami o aktywności przeciwdrobnoustrojowej. Realizacja tego celu jest moż-liwa dzięki zastosowaniu osiągnięć z zakresu nanotechnologii. Zwiększająca się liczba doniesień literaturowych potwierdza znaczną aktywność przeciwdrobnoustrojową nanocząstek polimerowych skoniugowanych z klasycznymi antybiotykami, co może zostać wykorzystane w terapii infekcji o charakterze bakteryjnym i grzybiczym, również tych wywoływanych przez patogeny lekooporne. Wysoka biokompatybilność nanocząstek polimerowych, a także możliwość zwiększania aktywności przeciwdrobnoustrojowej i poprawy parametrów farmakokinetycznych stosowanych obecnie chemioterapeutyków, wskazuje na możliwość zastosowania nanostruktur w nowoczesnej terapii chorób infekcyjnych. W niniejszej pracy podsumowano metody syntezy nanosystemów opartych na nanocząstkach polimerowych, a także opisano mechanizm ich działania. Przedstawione zostały również najnowsze osiągnięcia w syntezie nanocząstek skoniugowanych z antybiotykami, pozwalające na ich zastosowanie w terapii infekcji o charakterze bakteryjnym i grzybiczym.

show abstract

“…AmpB has a molecular weight of 924.08 Da, and thus, passive diffusion may be expected to be very low. 53 Moreover, AmpB is relatively unstable at the acidic pH of the gastrointestinal tract, and upon oral administration might be degraded prior to absorption. In addition, it undergoes extensive P-gp efflux from the enterocytes, which further limits its oral bioavailability.…”

Section: Nanostructured Anti-leishmania Delivery Systemsmentioning

confidence: 99%

Nanostructured delivery systems with improved leishmanicidal activity: a critical review

Bruni¹,

Stella²,

Giraudo³

et al. 2017

IJN

View full text Add to dashboard Cite

Leishmaniasis is a vector-borne zoonotic disease caused by protozoan parasites of the genus Leishmania , which are responsible for numerous clinical manifestations, such as cutaneous, visceral, and mucocutaneous leishmaniasis, depending on the site of infection for particular species. These complexities threaten 350 million people in 98 countries worldwide. Amastigotes living within macrophage phagolysosomes are the principal target of antileishmanial treatment, but these are not an easy target as drugs must overcome major structural barriers. Furthermore, limitations on current therapy are related to efficacy, toxicity, and cost, as well as the length of treatment, which can increase parasitic resistance. Nanotechnology has emerged as an attractive alternative as conventional drugs delivered by nanosized carriers have improved bioavailability and reduced toxicity, together with other characteristics that help to relieve the burden of this disease. The significance of using colloidal carriers loaded with active agents derives from the physiological uptake route of intravenous administered nanosystems (the phagocyte system). Nanosystems are thus able to promote a high drug concentration in intracellular mononuclear phagocyte system (MPS)-infected cells. Moreover, the versatility of nanometric drug delivery systems for the deliberate transport of a range of molecules plays a pivotal role in the design of therapeutic strategies against leishmaniasis. This review discusses studies on nanocarriers that have greatly contributed to improving the efficacy of antileishmaniasis drugs, presenting a critical review and some suggestions for improving drug delivery.

show abstract

Biodegradable Nanoparticles Improve Oral Bioavailability of Amphotericin B and Show Reduced Nephrotoxicity Compared to Intravenous Fungizone®

Abstract: Together, these results offer a possibility of treating systemic fungal infection and leishmaniasis with oral AMB-NP, which could revolutionize the infectious disease treatment modalities.

Cited by 127 publications

References 22 publications

Critical Process Parameters Evaluation of Modified Nanoprecipitation Method on Lomustine Nanoparticles and Cytostatic Activity Study on L132 Human Cancer Cell Line

Critical Process Parameters Evaluation of Modified Nanoprecipitation Method on Lomustine Nanoparticles and Cytostatic Activity Study on L132 Human Cancer Cell Line

Polymeric nanoparticles – a novel solution for delivery of antimicrobial agents

Nanostructured delivery systems with improved leishmanicidal activity: a critical review

Contact Info

Product

Resources

About